RCT: Effect of ramipril on walking times and QoL in patients with peripheral artery disease and intermittent claudication:

Source: JAMA Area: News Approximately one-third of patients with peripheral artery disease (PAD) experience intermittent claudication, with consequent loss of quality of life (QoL).   This multicentre randomised, double-blind, placebo-controlled trial evaluated the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and QoL in 212 Australian patients with PAD (mean age 65.5 years).   Patients were randomised to receive ramipril (10mg/day; n = 106) or matching placebo (n = 106) for 24 weeks. Patients were observed for two prespecified primary outcomes, maximum and pain-free walking times assessed during a standard treadmill test.   The following results were reported:   . At 6 months, ramipril was associated with a statistically significant increase in mean pain-free walking time (75-second; 95% CI, 60-89 seconds; P < .001) and maximum walking time (255-second; 95% CI, 215-295 seconds; P < .001) compared to ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news